Embecta Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY Revenue (est.)
$1Bnext fiscal year
FY EPS (est.)
$1.59next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 Fiscal Year 2026 Earnings Release | 27 Nov 2026 |
Monitoring Framework
Key Performance Indicators
U.S. Revenue Growth (Adjusted Constant Currency) Quarterly-2,940.0%
Adjusted Gross Margin Quarterly5,940.0%
Owen Mumford Revenue Contribution Annually30M
Watch Items
- U.S. retail market share stabilization and competitive pricing pressure on core pen needle productsTrigger: Further volume declines or loss of additional major retail accountsAction: Accelerate commercial execution under new North America leadership and evaluate pricing strategies
- Integration of Owen Mumford and commercialization of the Aidaptus auto-injector platformTrigger: Delays in regulatory approvals or slower-than-expected onboarding of pharmaceutical partnersAction: Leverage global commercial infrastructure and large-scale manufacturing expertise to drive adoption
- Impact of GLP-1 drugs on long-term insulin delivery demandTrigger: Accelerating shift in diabetes care landscape reducing overall pen needle market volumeAction: Diversify product portfolio into broader chronic care markets including obesity and autoimmune diseases
Research as of 19 Jun 2026